Addex Therapeutics (ADXN) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free ADXN Stock Alerts $8.79 -0.21 (-2.33%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12, 2024 | americanbankingnews.comAddex Therapeutics Ltd (NASDAQ:ADXN) Sees Large Drop in Short InterestMay 8, 2024 | globenewswire.comAddex to Present at Bio€quity Europe 2024May 8, 2024 | morningstar.comAddex Therapeutics Ltd ADR ADXNApril 29, 2024 | msn.comTech Rally Subsides as US Equity Futures Waver Pre-BellApril 29, 2024 | msn.comAddex stock plunges 50% on failed study for epilepsy drugApril 29, 2024 | marketbeat.comTrading was temporarily halted for "ADXN" at 10:04 AM with a stated reason of "LULD pause."April 29, 2024 | finanznachrichten.deAddex Therapeutics: Addex Provides Update on ADX71149 Phase 2 Epilepsy StudyApril 29, 2024 | globenewswire.comAddex Provides Update on ADX71149 Phase 2 Epilepsy StudyApril 19, 2024 | globenewswire.comAddex to Present at the Swiss Biotech Day 2024April 18, 2024 | investorplace.comADXN Stock Earnings: Addex Therapeutics Reported Results for Q4 2023April 18, 2024 | seekingalpha.comAddex Therapeutics GAAP EPS of -CHF 0.14, revenue of CHF 1.65MApril 18, 2024 | globenewswire.comAddex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate UpdateApril 11, 2024 | globenewswire.comAddex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024April 3, 2024 | finanznachrichten.deNeurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological DisordersApril 3, 2024 | markets.businessinsider.comAddex Announces Launch Of Neurosterix In Partnership With Perceptive - Quick FactsApril 3, 2024 | globenewswire.comAddex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological DisordersMarch 14, 2024 | globenewswire.comAddex to Present at the Bio-Europe Spring 2024 ConferenceFebruary 22, 2024 | benzinga.comAddex Therapeutics Stock (NASDAQ:ADXN), Short Interest ReportJanuary 31, 2024 | finance.yahoo.comAddex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.January 9, 2024 | finance.yahoo.comAddex to Present at the Swiss Equities Baader ConferenceJanuary 5, 2024 | finance.yahoo.comAddex to Present at Biotech Showcase™ 2024December 23, 2023 | thestreet.comAddex Therapeutics LtdDecember 20, 2023 | finanznachrichten.deAddex Therapeutics: Addex Shareholders Approve All Resolutions at Extraordinary General MeetingDecember 20, 2023 | finance.yahoo.comAddex Shareholders Approve All Resolutions at Extraordinary General MeetingDecember 14, 2023 | finance.yahoo.comAddex Creates Treasury SharesDecember 5, 2023 | marketbeat.comTrading was temporarily halted for "ADXN" at 03:12 PM with a stated reason of "LULD pause."November 29, 2023 | msn.comAddex Therapeutics GAAP EPS of -CHF0.03, income of CHF0.33MNovember 29, 2023 | markets.businessinsider.comAddex Therapeutics Posts Narrower Loss In Q3 - Quick FactsNovember 29, 2023 | finance.yahoo.comAddex Reports Q3 2023 Financial Results and Provides Corporate UpdateNovember 28, 2023 | finance.yahoo.comAddex Convenes Extraordinary General MeetingNovember 23, 2023 | finance.yahoo.comAddex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023November 14, 2023 | finance.yahoo.comAddex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of PatientsNovember 2, 2023 | finance.yahoo.comAddex Announces Participation in the Bio-Europe 2023 ConferenceOctober 21, 2023 | finanznachrichten.deAddex Therapeutics: Addex Completes ADS Ratio ChangeOctober 20, 2023 | finance.yahoo.comAddex Completes ADS Ratio ChangeOctober 6, 2023 | markets.businessinsider.comAddex To Implement ADS Ratio ChangeOctober 5, 2023 | finance.yahoo.comAddex Therapeutics focused on securing new partnerships to fund promising treatmentsSeptember 25, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Addex Therapeutics (ADXN)September 6, 2023 | finance.yahoo.comAddex Announces Participation in the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 5, 2023 | benzinga.comAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024September 5, 2023 | finance.yahoo.comAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024September 4, 2023 | finance.yahoo.comAddex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in BrainAugust 10, 2023 | finanznachrichten.deAddex Therapeutics: Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate UpdateAugust 10, 2023 | finance.yahoo.comAddex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate UpdateAugust 9, 2023 | markets.businessinsider.comWhat Wall Street expects from Addex Therapeutics's earningsAugust 4, 2023 | finance.yahoo.comAddex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023August 3, 2023 | finance.yahoo.comAddex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research CollaborationJune 1, 2023 | finanznachrichten.deAddex Therapeutics: Addex Shareholders Approve All Resolutions at Annual General MeetingMay 11, 2023 | msn.comEarnings Scheduled For May 11, 2023May 11, 2023 | finance.yahoo.comAddex Reports Q1 2023 Financial Results and Provides Corporate Update Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. ADXN Media Mentions By Week ADXN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADXN News Sentiment▼1.030.55▲Average Medical News Sentiment ADXN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADXN Articles This Week▼31▲ADXN Articles Average Week Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aeterna Zentaris News NuCana News Alterity Therapeutics News Molecular Templates News Chemomab Therapeutics News Galera Therapeutics News Universe Pharmaceuticals News Guardion Health Sciences News Moleculin Biotech News MIRA Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADXN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMost important medical advance in 100 yearsThe Oxford ClubBill Clinton Backing Biden Replacement???The Freeport SocietyCharles Payne Demystifies OptionsUnstoppable ProsperityWhy Is Gold On a MASSIVE rally? Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
